ALX Oncology Holdings(ALXO)宣布同步推进两项独立临床试验的进展。其中一项试验旨在评估其研发的CD47抑制剂Evorpacept的疗效与安全性,另一项试验则聚焦于新型EGFR靶向抗体偶联药物ALX2004的临床验证。
这两项试验分别针对不同的肿瘤治疗机制。Evorpacept通过阻断CD47信号通路激活先天免疫系统,ALX2004则利用抗体偶联技术精准靶向EGFR高表达肿瘤细胞。公司表示,临床试验的并行推进将加速创新抗癌疗法的开发进程。
ALX Oncology Holdings(ALXO)宣布同步推进两项独立临床试验的进展。其中一项试验旨在评估其研发的CD47抑制剂Evorpacept的疗效与安全性,另一项试验则聚焦于新型EGFR靶向抗体偶联药物ALX2004的临床验证。
这两项试验分别针对不同的肿瘤治疗机制。Evorpacept通过阻断CD47信号通路激活先天免疫系统,ALX2004则利用抗体偶联技术精准靶向EGFR高表达肿瘤细胞。公司表示,临床试验的并行推进将加速创新抗癌疗法的开发进程。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.